This is a list of investigational hair loss drugs, or drugs that are currently under development for clinical use in the treatment of different forms of alopecia (hair loss), such as androgenetic alopecia (pattern hair loss) and alopecia areata (spot baldness), but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Route – Indication – Mechanism of Action [Reference]". This list was last comprehensively updated in July 2025. It is likely to become outdated with time.
Under development
Preregistration Coacillium (LH-8) – topical, other routes – alopecia areata, alopecia – various mechanisms of action Gecaxitinib (gecacitinib, jaktinib) – oral – alopecia areata – ACVR1 protein inhibitor, Janus kinase 1 inhibitor, Janus kinase 2 inhibitor, Janus kinase 3 inhibitor, TYK2 kinase inhibitor Ivarmacitinib (ARQ-252, ARQ-255, SHR-0302) – oral – alopecia areata – Janus kinase 1 inhibitor
Phase 3 AB-103 – topical – alopecia – minoxidil sulfotransferase stimulant (adjunct to minoxidil) Clascoterone (Breezula, Winlevi; CB-03-01) – topical – alopecia – androgen receptor antagonist Diphencyprone (diphenylcyclopropenone, samcyprone) – topical – alopecia areata – immunomodulator Dutasteride (AD-208) – oral – alopecia – 5α-reductase inhibitor Minoxidil oral extended-release (VDPHL01, VDPHL-01, VDPHL) – oral – alopecia, male pattern baldness – potassium channel opener (prodrug of minoxidil sulfate) Minoxidil sublingual (SLM) – sublingual – alopecia – potassium channel opener (prodrug of minoxidil sulfate) Pyrilutamide (EX-A5504, HY-145451, KX 826) – topical – alopecia – androgen receptor antagonist Upadacitinib (Rinvoq; ABT-494) – oral – alopecia areata – Janus kinase 1 inhibitor
Phase 2/3 Dalosirvat (SM-04554) – topical – alopecia – Wnt signalling pathway stimulant
Phase 2 Abatacept (Orencia) – injection – alopecia areata – T cell activation inhibitor Amlitelimab (KY-1005, SAR-445229) – subcutaneous injection – alopecia areata – OX40 ligand inhibitor BAY-1158061 (HMI-115) – subcutaneous injection – alopecia – prolactin receptor monoclonal antibody (prolactin receptor inhibitor) Bempikibart (ADX-914, BMS-986265) – subcutaneous injection – alopecia areata – CRLF2 protein antagonist, interleukin 7 receptor α subunit inhibitor Bimatoprost (Lumigan) – topical – alopecia – prostaglandin F receptor agonist (prostaglandin F2α analogue) Botulinum toxin A (Xeomin; incobotulinum toxin A) – intradermal – alopecia – acetylcholine release inhibitor and neuromuscular blocking agent CKD-498 – oral – alopecia – undefined mechanism of action Daxdilimab (HZN-7734; MEDI-7734; VIB-7734) – oral – alopecia areata – anti-ILT7 human monoclonal antibody/dendritic cell inhibitor Delgocitinib (Anzupgo, Corectim; JTE-052, LEO-124249, LP-0133) – unknown – alopecia areata – Janus kinase inhibitor Deucravacitinib (Sotyktu; BMS-986165) – oral – alopecia areata – TYK2 kinase inhibitor Finasteride/latanoprost/minoxidil (TH-07; Triple Hair) – topical – alopecia – combination drug/multiple mechanisms of action FOL-005 (osteopontin-derived peptide) – intradermal – alopecia – undefined mechanism of action GT-20029 (AR-PROTAC) – topical – alopecia – androgen receptor degradation enhancer KL-130008 – oral – alopecia areata – Janus kinase inhibitor Latanoprost (DLQ01; DLQ-01) – topical – androgenic alopecia – prostaglandin F receptor agonist (prostaglandin F2α analogue) NXC-736 – oral – alopecia areata – sphingosine 1 phosphate receptor antagonist Rezpegaldesleukin (Rezpeg; LY-3471851, NKTR-358) – unknown – alopecia areata – interleukin-2 conjugate/modulator RK-023 (nobiprostolan) – topical – alopecia, hypotrichosis – undefined mechanism of action (prostaglandin F2α analogue) Rosnilimab (ANB-030) – subcutaneous injection – alopecia areata – programmed cell death 1 receptor agonist Ruxolitinib (Jakafi, Jakavi, Opzelura; INCB-018424) – topical – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 2 inhibitor SIS-302-AA – unspecified – alopecia areata – undefined mechanism of action Suvomipic (PP405; PP-405; JXL069; JXL-069) – topical – alopecia – mitochondrial pyruvate carrier (MPC) inhibitor SYHX-1901 – oral – alopecia areata – Janus kinase inhibitor, Syk kinase inhibitor TDM-105795 (CU-40101) – topical – alopecia – thyroid hormone receptor agonist
Phase 1/2 ABS-201 – subcutaneous injection – alopecia – prolactin receptor monoclonal antibody Finasteride (IVL-3001, IVL-3002) – long-acting injection – alopecia – 5α-reductase inhibitor Finasteride (DA-4001, DA-4001C) – topical – alopecia – 5α-reductase inhibitor IMG-007 (HMPL-A28) – intravenous injection – alopecia areata – OX40 receptor antagonist
Phase 1 AH-001 – topical – alopecia – ubiquitin-protein ligase expression stimulant AMP-303 – intradermal – alopecia – undefined mechanism of action (polysaccharide) CKD-843 – oral, injection – alopecia – undefined mechanism of action CKR-051 – transdermal – alopecia – CXXC5 protein inhibitor, Wnt signalling pathway stimulant DR-01 – parenteral – alopecia areata – antibody-dependent cell cytotoxicity, T lymphocyte stimulant ET-02 (RS-5441) – topical – alopecia, hair disorders – undefined mechanism of action (targets and restores hair follicle stem cells) FOL-100 – topical – alopecia – undefined mechanism of action OLX-72021 – intradermal injection – alopecia – RNA interference QY-201 – oral – alopecia areata – Janus kinase 1 inhibitor, TYK2 kinase inhibitor SCO-240 – oral – alopecia – somatostatin receptor 5 modulator Squaric acid dibutyl ester (SQX-770) – topical – alopecia areata – immunomodulator VDAA – topical – alopecia areata – undefined mechanism of action
Phase 0 Latanoprost/minoxidil (ANR-001.1) – topical – hypotrichosis – combination drug/multiple mechanisms of action
… excerpt ends here. Continue reading the full article.
